|
Improves the efficacy of current immunotherapies by individually targeting T cell receptors proteins
Creates a therapy that boasts a higher chance of survival compared to the standard of care for acute myeloid leukemia
Abstract
USC researchers created genetically engineered exosomes (SMART-Exos) that display two distinct monoclonal antibodies targeting...
|